KRAS and neoplasm: The obtained data revealed that ovarian cancer patients with more aggressive clinicopathological data, including (advanced stage (III&IV), grade (II), lymph node invasion, big tumor size (T3&T4), and metastatic status (M1), had a remarkably elevation in KRAS expression level.